Recombinant Human Anti-PD-1 Monoclonal Antibody HX008 Injection for the Treatment of Advanced Solid Tumors
|
|
文献详情
编号/登记号：
注册时间：
研究开始时间：
研究结束时间：
项目类型：
本院角色：
多中心研究：
招募状态：
试验分期：
研究疾病/适应症：
研究类型：
研究单位：[1]Taizhou Hanzhong biomedical co. LTD[2]Affiliated Hospital of Hebei University Baoding, China[3]Beijing Yuhe Combination of Chinese Traditional and Western Medicine Recovery Hospital Beijing, China[4]The First Affiliated Hospital of Bengbu Medical College Bengbu, China[5]Hunan Cancer Hospital Changsha, China[6]Xiangya Hospital, Central South University Changsha, China[7]Heping Hospital Affiliated to Changzhi Medical College Changzhi, China[8]Fujian Cancer Hospital Fuzhou, China[9]The First Affiliated Hospital, Zhejiang University School of Medicine Hangzhou, China[10]Zhejiang Cancer Hospital Hangzhou, China[11]The affiliated Cancer Hospital of Harbin Medical University Harbin, China[12]Anhui Provincial Cancer Hospital Hefei, China[13]Shandong Cancer Hospital Jinan, China[14]Jiangsu Provincial People's Hospital Nanjing, China[15]Guangxi Medical University Cancer Hospital Nanning, China[16]Fudan University Cancer Center Shanghai, China[17]Liaoning Cancer Hospital Shenyang, China[18]The First Hospital of China Medical University Shenyang, China[19]Peking university shenzhen hospital Shenzhen, China[20]The Fourth Hospital of Hebei Medical University Shijiazhuang, China河北医科大学第四医院[21]The Second Affiliated Hospital of Soochow University Suzhou, China[22]Shanxi Cancer Hospital Taiyuan, China[23]Tianjin Cancer Hospital Tianjin, China[24]Tianjin People's Hospital Tianjin, China[25]Hubei Cancer Hospital Wuhan, China[26]Wuhan Central Hospital Wuhan, China[27]The First Affiliated Hospital of Xi'an Jiaotong University Xian, China[28]The First Affiliated Hospital of Xinxiang Medical College Xinxiang, China[29]Henan Cancer Hospital Zhengzhou, China[30]The First Affiliated Hospital of Zhengzhou University Zhengzhou, China[31]Cancer Hospital, Chinese Academy of Medical Sciences Beijing, Beijing, China, 100021
研究目的：
In this study, patients of advanced gastric adenocarcinoma with failed first-line chemotherapy-line or advanced mismatched repair deficient (dMMR) or microsatellite instability-high (MSI-H) advanced solid carcinoma will be treated with HX008 combined with irinotecan and HX008 monotherapy There will be two cohorts in this study: Cohort 1 and Cohort 2. For Cohort 1, advanced gastric adenocarcinoma with failed first-line chemotherapy-line cancer participants, who had failed or were unable to tolerate first line chemotherapy with platinum-based or fluorouracil regimens. For Cohort 2, advanced solid tumor participants, who are required to have been previously treated with at least one line of systemic standard of care therapy
